SAFETY OF OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS OVER TIME: POOLED ANALYSIS FROM PHASE 2, PHASE 3, AND OPEN-LABEL EXTENSION TRIALS

被引：0
|
作者：
D'Haens, Geert R.
Colombel, Jean Frederic
Lichtenstein, Gary R.
Charles, Lorna
Petersen, AnnKatrin
Ather, Shabana
Kollengode, Kanthi
Hsu, Kate
Irving, Peter M.
Danese, Silvio
机构：
来源：
GASTROENTEROLOGY | 2021年 / 160卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
128
引用
收藏
页码：S35 / S35
页数：1
相关论文
共 50 条
  • [21] Hepatic Safety of Ozanimod in Ulcerative Colitis and Relapsing Multiple Sclerosis Phase 3 Trials
    Rubin, David T.
    Caldera, Freddy
    Cohen, Jeffrey
    Zeuzem, Stefan
    Cheng, Chun-Yen
    Ather, Shabana
    Charles, Lorna
    Sheffield, James K.
    Dignass, Axel
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S581 - S581
  • [22] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis in daybreak: an open-label extension study of ozanimod phase 1-3 trials
    Selmaj, K.
    Steinman, L.
    Comi, G.
    Bar-Or, A.
    Arnold, D.
    Hartung, H. P.
    Montalban, X.
    Havrdova, E.
    Sheffield, J.
    Chen, T.
    Minton, N.
    Silva, D.
    Kappos, L.
    Cohen, J.
    Cree, B.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 223 - 223
  • [23] BOWEL URGENCY OUTCOMES ARE ASSOCIATED WITH IMPROVEMENT IN FATIGUE IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: A POOLED ANALYSIS OF LUCENT-1 AND LUCENT-2 PHASE 3 TRIALS
    Rubin, David T.
    Hindryckx, Pieter
    Hibi, Toshifumi
    McGinnis, Kim
    Gibble, Theresa H.
    Keohane, Anthony
    Regueiro, Miguel D.
    GASTROENTEROLOGY, 2023, 164 (06) : S213 - S213
  • [24] EFFICACY AND SAFETY OF MIRIKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-2 STUDY
    Dubinsky, Marla C.
    Irving, Peter M.
    Li, Xingyuan
    Howaldt, Stefanie
    Pokrotnieks, Juris
    Krueger, Kathryn A.
    Laskowski, Janelle
    Lissoos, Trevor
    Milata, Joe
    Morris, Nathan
    Arora, Vipin
    Milch, Catherine
    Sands, Bruce E.
    GASTROENTEROLOGY, 2022, 162 (07) : S1393 - S1394
  • [25] Efficacy and safety of mirikizumab as maintenance therapy in patients with moderately to severely active ulcerative colitis: Results from the Phase 3 LUCENT-2 study
    Begun, J.
    Dubinsky, M. C.
    Irving, P. M.
    Li, X.
    Howaldt, S.
    Pokrotnieks, J.
    Krueger, K.
    Laskowski, J.
    Lissoos, T.
    Milata, J.
    Morris, N.
    Arora, V.
    Milch, C.
    Sands, B. E.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 133 - 133
  • [26] MIRIKIZUMAB PHARMACOKINETICS AND EXPOSURE-RESPONSE RELATIONSHIPS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM RANDOMISED PHASE 2 AND PHASE 3 INDUCTION AND MAINTENANCE TRIALS
    Friedrich, Stuart
    Chua, Laiyi
    Zhang, Xin
    GASTROENTEROLOGY, 2023, 164 (06) : S1217 - S1218
  • [27] Mirikizumab pharmacokinetics and exposure-response relationships in patients with moderately to severely active ulcerative colitis: results from randomised phase 2 and phase 3 induction and maintenance trials
    Friedrich, S.
    Chua, L.
    Zhang, X. C.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 646 - 646
  • [28] Long-term Safety and Tolerability of Ozanimod by Age Category in Patients With Relapsing Multiple Sclerosis From Two Phase 3 Trials and an Open-Label Extension Study
    Selmaj, K. W.
    Cohen, J. A.
    Steinman, L.
    Comi, G.
    Bar-Or, A.
    Hartung, H.
    Montalban, X.
    Kappos, L.
    Sheffield, J. K.
    Krakovich, A.
    Cheng, C.
    Riolo, J.
    Silva, D.
    Cree, B. A.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 56 - 57
  • [29] Risankizumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomised Phase 3 COMMAND Study
    Louis, E.
    Panaccione, R.
    Parkes, G.
    Peyrin-Biroulet, L.
    Ferrante, M.
    Hisamatsu, T.
    Siegmund, B.
    Kalabic, J.
    Levine, P.
    Neimark, E.
    Wallace, K.
    Chen, S.
    Cheng, L.
    Duan, W. R.
    Armuzzi, A.
    Biederman, L.
    Loftus, E.
    Melmed, G.
    Schreiber, S.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I10 - I12
  • [30] Risankizumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomized Phase 3 INSPIRE Study
    Louis, Edouard
    Panaccione, Remo
    Parkes, Gareth
    Peyrin-Biroulet, Laurent
    Ferrante, Marc
    Takeuchi, Ken
    Siegmund, Britta
    Levine, Phillip
    Kalabic, Jasmina
    Neimark, Ezequiel
    Wallace, Kori
    Chen, Su
    Duan, W. Rachel
    Armuzzi, Alessandro
    Biedermann, Luc
    Loftus, Edward V.
    Melmed, Gil
    Schreiber, Stefan
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S624 - S625
12345